Matt Hoffman, Associate Editorial Director for NeurologyLive®, has covered medical news for MJH Life Sciences, NeurologyLive®’s parent company, since 2017. He hosts the NeurologyLive® Mind Moments® podcast, as well as the Medical World News show, Deep Dive. Follow him on Twitter @byMattHoffman or email him at mhoffman@neurologylive.com
Apomorphine Sublingual Film Treatment for Parkinson Disease May Not Require Use of Antiemetics
June 20th 2022After a protocol adjustment that disallowed the use of the antiemetic trimethobenzamide during dose-titration, adverse event data from an open-label study of apomorphine sublingual film (Kynmobi; Sunovion) suggest antinausea treatment might not be necessary.
The Future of Parkinson Disease Therapies and the Challenges With Stem Cell Therapies
June 19th 2022In a presentation at the 2022 ATMRD Congress, Rajesh Pahwa, MD, FANA, FAAN, spoke about the hope held for stem cell approaches and the potential to improve care with several therapies with possible approvals on the horizon.
Physician Estimates of Needle Phobia Might Be Overstated Among Patients With Parkinson Disease
June 18th 2022A survey of more than 4000 individuals with PD and their caregivers suggests that almost 90% would be willing to use subcutaneous injectable therapies to control their disease, contrasting the current anecdotal belief of “needle phobia” in this population.
The Importance of Treatment Nuance and Novel Options in Treating Parkinson Disease
June 18th 2022In a presentation at the 2022 ATMRD Congress, Jill Farmer, DO, MPH, outlined several novel options for the treatment of OFF episodes in Parkinson disease, and stressed the need for individualized approaches to maximize patient quality of life.
Tremeau Pharmaceuticals Gets IND Go-Ahead for Rofecoxib Reformulation, Dubbed TRM-201
June 15th 2022The oral tablet formulation of rofecoxib has been shown to reach maximum plasma concentrations at 2 hours post dose compared with 3 for the historical formulation, which the company believes can improve the time to onset of action.
Children, Adolescents With Migraine Show High Risk for Anxiety and Depression Symptoms
June 14th 2022A systematic review and meta-analysis suggested that the risk of anxiety and depressive symptoms was nearly doubled for those with migraine compared with healthy controls, indicating a need to screen this patient population.
Aberrant Sleep Patterns Show Risk Associated With Status Migrainosus Recurrence
June 11th 2022Data from a study in Olmsted County, Minnesota, identified the incidence rate of status migrainosus to be 26.60 per 100,000, with more than 10% of the cohort reporting that too much or too little sleep triggered the condition.
Rimegepant Is Well-Tolerated and Safe for Migraine Over 1 Year With Every-Other-Day Dosing
June 10th 2022Patients in the open-label extension also showed limited need for acute treatment with rimegepant (Nurtec ODT; Biohaven Pharmaceuticals), as more than 80% of patients took 16 or fewer total tablets over the 28-day period.